Navigation Links
GlaxoSmithKline Implements Next Phase of New Incentive Compensation Program for U.S. Sales Representatives
Date:7/5/2011

RESEARCH TRIANGLE PARK, N.C., July 5, 2011 /PRNewswire/ -- GlaxoSmithKline (NYSE: GSK) today announced that it has implemented the next phase of its new incentive compensation program for professional sales representatives with the introduction of a new performance evaluation methodology and process.  

In January 2011, GSK eliminated individual sales goals as part of the company's incentive compensation program for sales professionals who work directly with healthcare professionals.  Beginning July 1, GSK is putting in place a new method for evaluating sales professionals' performance and bonus in alignment with the company's values of transparency, respect for people, integrity and focus on the patient.  

Under the new system, GSK's sales professionals who work directly with healthcare providers will continue to be compensated with a competitive mix of salary and bonus.  In place of individual sales targets, three primary factors will be evaluated to assess performance and determine bonuses: selling competency, customer evaluations, and the overall performance of their business unit.

"Our sales professionals play a critical role in providing doctors with appropriate, updated information on the safety and benefits of our medicines.  This information helps doctors make informed treatment decisions for their patients," said Deirdre Connelly, President, North America Pharmaceuticals, GlaxoSmithKline. "This industry-leading incentive program aligns our performance measures and rewards with our values so doctors can be confident that our sales professionals are focused on improving patient health."

Since first announcing its plans in July 2010 to radically change its sales incentive compensation system, GSK has conducted extensive research to define how best to obtain robust, ongoing, unbiased assessments of the effectiveness of its sales professionals in meeting customer needs. This effort is part of a wider evolution to align the company's sales and marketing programs with societal and customer expectations.

"Along with changing many aspects of how we conduct our business, we have also invested heavily in training and compliance programs to ensure that we are operating at or above the pharmaceutical industry code of ethics," Connelly said.

GlaxoSmithKline – one of the world's leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer.  For further information go to us.gsk.com, follow us on twitter.com/GSKUS or visit our blog (www.morethanmedicine.us.gsk.com/blog/).

Cautionary statement regarding forward-looking statements

Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK' s operations are described under 'Risk Factors' in the 'Business Review' in the company' s Annual Report on Form 20-F for 2010.


'/>"/>
SOURCE GlaxoSmithKline
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
2. GlaxoSmithKline Accelerates Review of Exelixis XL880
3. New Data Show That GlaxoSmithKlines Rotarix(R) Could Be Given With Other Routine Infant Vaccines in the U.S.
4. Coley Pharmaceutical Group Receives $3.0 Million Milestone Payment from GlaxoSmithKline
5. GlaxoSmithKline and Theravance Announce Start of Large Phase 2B ICS and LABA Studies for Asthma in the Horizon Program
6. Paul Capital Healthcare Purchases Additional Royalty Interest in GlaxoSmithKlines Rotarix(R)
7. GlaxoSmithKline Reports Further Progress of Oncology Portfolio
8. GlaxoSmithKline Announces New Drug Application and Phase III Results for Rezonic(TM)/Zunrisa(TM) (Casopitant)
9. GlaxoSmithKline Collaborates with National Cancer Institute to Make Large Body of Cancer Cell Genomic Data Available to All Cancer Researchers
10. GlaxoSmithKline Responds to FDA on CERVARIX(R) and Plans to Submit Final Study Data for Approval
11. Genmab and GlaxoSmithKline Announce Positive Top-Line Results in Ofatumumab Chronic Lymphocytic Leukemia Pivotal Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... LG Innotek hat heute die weltweit erste ... das 1,5-fache des 45-mW-Moduls der Konkurrenz. UV-C ... und 280 nm und eignet sich damit für Sterilisationsaufgaben. Es ... zerstört. Das Produkt von LG Innotek erzeugt UV-Strahlung im ... ...
(Date:2/23/2017)... -- ITL Limited, ( ASX: ITD ), an innovative diversified healthcare ... ended 31 December 2016 compared with the previous corresponding period. A ... here . Highlights ... Earnings per share of 2.2 cents (Dec 2015: 1.2 ... $15.7m; up 11%) Profit before tax of $2.12m ...
(Date:2/23/2017)... 2017 Research and Markets has announced the addition ... report to their offering. ... The latest research Menopause Drugs Price Analysis and Strategies - 2016, provides ... research answers the following questions: What are ... they positioned in the Global Menopause market? What are ...
Breaking Medicine Technology:
(Date:2/24/2017)... ... February 24, 2017 , ... The narrative in “ ... Erik Schanssema ’s true account of his paramedic experiences. Schanssema describes the tragedies he ... and his attempts to overcome them. , Schanssema, initially unsure of the career path ...
(Date:2/24/2017)... (PRWEB) , ... February 24, 2017 , ... The International ... 7th annual “Imagine Me Beyond What You See” body image mannequin art competition. Selected ... will be showcased and the winner revealed at the 31st annual iaedp Symposium, March ...
(Date:2/24/2017)... ... February 24, 2017 , ... Congratulations to ... Elite division on February 12th. Ms. Esparza qualified into this prestigious status ... competition held in Las Vegas, Nevada. Frida is one of approximately 25 gymnasts ...
(Date:2/23/2017)... (PRWEB) , ... February 23, 2017 , ... The 89th ... the winner of the 2016 National Education Policy Center Bunkum Award. We invite you ... in 2016. , This year’s Bunkum winner is the Center for American Progress (CAP), ...
(Date:2/23/2017)... Angeles, CA (PRWEB) , ... February 23, 2017 , ... ... first two episodes of WE TV’s “Mama June: From Not to Hot,” which will ... TV notable, “Mama” June Shannon, known to millions from the 2012 reality television series, ...
Breaking Medicine News(10 mins):